

# The Pharm Voice

Pharmaceutical Industry discussion, review, analysis, news and information.

Search this blog:

RSS Feed:



[Subscribe](#)  
[What's this?](#)

Enter

[What's](#)

Sponsor this blog

« [New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ \(telbivudine\), USFDA-Approved](#) | [Main](#) | [European Patent Office Supports Validity of Pfizer's Lipitor® Patent](#) »

OCT  
28

## Wyeth: One of the U.S. EPA's Best Workplaces for Commuters

[GLORIA GAMAT](#) ♦ [October 28, 2006](#)

Know More: [News & Events](#)

[Wyeth](#) (NYSE: [WYE](#)) has been included in the [U.S. Environmental Protection Agency's](#) (EPA) list of "**Best Workplaces for Commuters**" from the [Fortune 500 Companies](#) for the third consecutive year.

Jumping six spots to the 13th position on the 2006 ranking, Wyeth also topped the list among

pharmaceutical companies.

The top 20 Fortune 500 Companies are recognized by the EPA for providing outstanding commuter benefits, such as subsidized transit/van pool passes, shuttles to their employees, ride matching and preferred parking for carpools.

The EPA has recognized Wyeth facilities in Collegeville and Great Valley, Pa.; Madison, N.J.; Pearl River, N.Y.; Sanford, N.C.; and Andover and Cambridge, Mass.; as locations that provide the highest level of commuting options for employees.

Steven Tasher, Vice President, Environmental Affairs and Facilities Operations and Associate General Counsel of Wyeth, commented:

"For the third consecutive year, Wyeth is being

recognized for its commitment to being socially responsible and environmentally conscious by supporting employee commuter programs that will continue to reduce road congestion and vehicle emissions."

Source: [PR Newswire](#)

[Digg this](#) • [Subscribe to this feed](#) • [Add to del.icio.us](#) • [Email this](#)

#### RECENT POSTS

- [European Patent Office Supports Validity of Pfizer's Lipitor® Patent](#)
- [Wyeth: One of the U.S. EPA's Best Workplaces for Commuters](#)
- [New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ \(telbivudine\), USFDA-Approved](#)
- [Laureate Pharma Extended its PROSTASCINT® Manufacture Agreement with Cytogen Corp.](#)
- [Auxilium Pharmaceuticals, Inc.'s Injectable Enzyme against Peyronie's Disease: AA4500, Passed Phase II Studies](#)

#### POST A COMMENT

Name, Email Address, and URL are not required fields.

Name (optional):

Email Address (optional):

URL (optional):

☐ Remember personal info?

Comments:

(you may use HTML tags for style)

Preview

Post

« [New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ \(telbivudine\), USFDA-Approved](#) | [Main](#) | [European Patent Office Supports Validity of Pfizer's Lipitor® Patent](#) »

#### ADVERTISE

#### RECENT COMMENTS

#### KNO

- Stephanie Kuhn on [GlaxoSmithKLine Submitted Supplemental New Drug Application for Advair Diskus® in COPD](#) [Vie](#) [Ne](#) [\\*V](#) [Ad](#) [Adl](#) [Ac](#) [Do](#) [Bu](#) [ALi](#) [An](#) [Biz](#) [Bu](#) [Do](#) [Bu](#) [The](#) [The](#) [Bu](#) [Bu](#) [Bu](#) [Ro](#) [Bu](#) [Sis](#) [Wo](#) [Cu](#) [Cu](#) [Hel](#) [En](#) [Biz](#) [Ent](#) [Wo](#) [Biz](#) [Eth](#) [Itsl](#)
- Mrs. J. McSorley on [Ohm Labs Inc. \(a Ranbaxy Laboratories Limited subsidiary\) Bagged Prestigious 'Private Label Supplier of the Year Award' from AmerisourceBergen](#)
- Diabi Mohamadou on [CV Therapeutics, Inc. Terminated Co-Promotion of ACEON® \(perindopril erbumine\) Tablets with Solvay Pharmaceuticals, Inc.](#)
- Randal Alexander on [Cephalon Inc.'s FENTORA\(TM\) \(fentanyl buccal tablet\) for Management of Breakthrough Pain in Patients with Cancer: Granted USFDA Approvable Letter](#)
- ho-joon on [Resveratrol: Anti-aging Wine Compound](#)